Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1995
Cash & Equivalents	2,730	3,106	2,886	2,194	1,618	1,468	812.7	535.2	809.1	648.72	Upgrade
Short-Term Investments	8,115	4,636	2,809	1,393	1,597	1,342	596.8	503.48	236.12	251.76	Upgrade
Cash & Cash Equivalents	10,845	7,742	5,695	3,587	3,214	2,810	1,410	1,039	1,045	900.48	Upgrade
Cash Growth	40.07%	35.96%	58.76%	11.60%	14.39%	99.35%	35.70%	-0.63%	16.07%	29.76%	Upgrade
Receivables	5,667	5,329	6,037	4,115	2,786	2,243	1,974	1,612	1,468	976.37	Upgrade
Inventory	2,581	2,402	1,951	1,917	1,416	1,151	726.1	399.36	238.58	128.86	Upgrade
Other Current Assets	386.6	411.2	332.4	160.8	273.7	243.3	225.1	130.53	163.5	79.05	Upgrade
Total Current Assets	19,479	15,884	14,015	9,779	7,689	6,448	4,335	3,180	2,915	2,085	Upgrade
Property, Plant & Equipment	4,146	3,763	3,482	3,222	2,890	2,576	2,359	2,083	1,594	974.31	Upgrade
Long-Term Investments	5,397	6,592	6,838	3,136	3,257	1,755	1,487	864.26	632.16	460.15	Upgrade
Goodwill and Intangibles	1,039	915.5	6.7	0	0	0	0	0	0	0	Upgrade
Other Long-Term Assets	3,020	2,060	1,093	1,027	968.9	956.1	584.2	845.6	467.76	318.45	Upgrade
Total Long-Term Assets	13,601	13,330	11,420	7,384	7,116	5,287	4,429	3,793	2,694	1,753	Upgrade
Total Assets	33,080	29,215	25,435	17,163	14,805	11,735	8,764	6,973	5,609	3,838	Upgrade
Accounts Payable	606.6	589.2	564	475.5	418.1	218.2	178.2	879.1	644.11	483.49	Upgrade
Deferred Revenue	585.6	547.7	515.3	635.5	487.4	916.7	949.3	1,062	818.17	209.27	Upgrade
Current Debt	0	0	719.7	0	0	0	0	129.56	0	0	Upgrade
Other Current Liabilities	2,231	2,004	2,134	1,586	1,191	307.9	8	-829.59	-651.12	-38.1	Upgrade
Total Current Liabilities	3,423	3,141	3,933	2,697	2,097	1,443	1,136	1,241	811.16	654.66	Upgrade
Long-Term Debt	2,703	2,701	1,980	2,696	713.9	708.5	703.5	351.57	362.92	457.71	Upgrade
Other Long-Term Liabilities	980.8	707.8	753.5	744.9	905	825.9	781.2	931.16	780.21	175.05	Upgrade
Total Long-Term Liabilities	3,684	3,409	2,734	3,441	1,619	1,534	1,485	1,283	1,143	632.76	Upgrade
Total Liabilities	7,107	6,551	6,666	6,138	3,716	2,977	2,620	2,524	1,954	1,287	Upgrade
Total Debt	2,703	2,701	2,700	2,696	713.9	708.5	703.5	481.13	362.92	457.71	Upgrade
Debt Growth	0.06%	0.06%	0.15%	277.60%	0.76%	0.71%	46.22%	32.57%	-20.71%	-9.29%	Upgrade
Retained Earnings	27,260	23,307	18,968	10,893	7,380	5,254	2,947	1,748	852.7	216.64	Upgrade
Comprehensive Income	-80.9	-238.8	-26.2	29.3	21.1	-12.3	0.6	-12.84	8.57	52.25	Upgrade
Shareholders' Equity	25,973	22,664	18,769	11,025	11,090	8,757	6,144	4,449	3,655	2,550	Upgrade
Net Cash / Debt	8,142	5,041	2,995	891.3	2,500	2,101	706	557.56	682.3	442.77	Upgrade
Net Cash / Debt Growth	61.52%	68.31%	236.03%	-64.35%	18.99%	197.65%	26.62%	-18.28%	54.10%	133.76%	Upgrade
Net Cash Per Share	71.61	44.41	26.69	7.74	21.82	18.30	6.09	4.79	5.92	3.90	Upgrade
Working Capital	16,056	12,743	10,082	7,082	5,593	5,005	3,200	1,939	2,104	1,430	Upgrade
Book Value Per Share	243.42	211.62	177.57	102.47	101.55	81.16	57.80	42.49	35.46	25.35	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).